Facebook Twitter LinkedIn
CIS

CIS

The science and practice of human immunology

The science and practice of human immunology
| MENU |

Share a Resource
Submit material for the education materials pages. Material will be reviewed by the Communications Committee before posting.

Clin Imm Sōsh: February 2016

Clin Imm Sōsh: Pointing you in the right direction
February 2016

Welcome to Clin Imm Sōsh, the quarterly e-newsletter from CIS! We like to keep you up to date on CIS's projects and committees, as well as let you know what's new on the website and social media. As always, we value your input, so if there are topics you'd like to see more (or less!) of in the newsletter, or you have any other comments, please drop us a line at info@clinimmsoc.org.


2016 Annual Meeting

CIS is excited to remind you that you can still register for the 2016 the Annual Meeting. In the Annual Meeting section of the CIS website, you can:


2016 Membership Renewal

Clinical Immunology Society (CIS) 2016 membership renewal is still available! CIS encourages you to renew your membership now to ensure that your membership investment will continue through December 31, 2016 and that your membership rights and benefits will not be interrupted. Benefits of CIS membership include:

  • The lowest registration rates for the 2016 CIS Annual Meeting
  • Reduced dues rates for CIS Partner Societies, including ESID, LASID and ASCIA
  • Online access to the Journal of Clinical Immunology, plus the option to receive print copies
  • Opportunities to serve on CIS committees
  • Networking with leading members of the international immunology community
  • Quarterly CIS newsletters

Please visit the Members Only Section to submit your 2016 dues online or to print an invoice to mail your payment. To access the Members Only Section you will need your log in information. If you have forgotten your username or password, please click the login help link on the Members Only login page.


CME available for Journal of Clinical Immunology articles

We are happy to announce that the Journal of Clinical Immunology (JoCI) is now publishing invited review articles written by internationally known experts in the field of primary immunodeficiency diseases. These articles offer continuing medical education credits. Each article is accompanied by five multiple choice questions consisting of one correct answer and four distractors that must be answered and then submitted for CME credit. The completion and submission of answers to these five questions will provide 1 CME credit per review article. A score of 80% (4 out of 5 correct answers) is required to receive CME credit.

To view the articles available for CME credits, please click here.


CIS Case Conference Webinar Series

CIS is proud to continue our Case Conference Webinar Series on February 23, at 8:00 pm ET. Hosted by the PID Summer School faculty and graduates, this interactive electronic format emphasizes discussion of interesting cases where we can all learn from each other. Registration is free and all are welcome! To register for the February 23 webinar, visit http://anymeeting.com/PIID=EC53D686834A38

Additionally, we are happy to provide recordings of our past webinars on the CIS website. To view any (or all seven) of our past webinars, please visit http://www.clinimmsoc.org/education/webinars.

Please note: CME is not offered for this webinar series, whether live or recorded.


CIS at the Fourth Meeting of the Latin American Society for Immunodeficiencies (LASID2015)

In November of 2015, the Latin American Society for Immunodeficiencies (LASID) held its fourth biennial meeting in the exciting city of Buenos Aires (Argentina), in a joint assembly with the Argentinian Society for Immunology (SAI) and the French-Argentinian Immunology Congress (FAIC). The meeting brought together more than 1200 researchers, physicians, medical and research graduates, postdocs, members of the industry and individuals from several patient organizations from more than 28 countries around the globe.

Over three days, cutting edge research and the latest clinical advancements in the field of PID were presented, attended and discussed. Topics covering diagnosis, treatment, awareness, advocacy and many more were introduced in the form of symposia, conferences, round tables, oral presentations, posters, junior activities and clinical case presentations. From all the abstracts submitted, 150 were selected and are available (as well as from previous LASID meetings) in a supplement of the Journal of Clinical Immunology, the official journal of CIS [J Clin Immunol, 2015. 35 (Suppl 1): S1–S57].

The Clinical Immunology Society has been actively participating as a partner Society in all LASID meetings since the first one was held in 2009. CIS's contributions to LASID2015 included the sponsoring of CIS members as keynote speakers, and many CIS members attended including several past presidents and council members, as well as the current and the incoming President. All of them made vital contributions to the scientific program, playing a major role in the success of our meeting. LASID is grateful to CIS for its invaluable participation, and acknowledges the importance of this partnership for the present and future of the patients affected with these diseases in the Americas and beyond.

On behalf of LASID:

José Luis Franco R, MD PhD
LASID Past President 2013-2015

Antonio Condino-Neto, MD PhD
LASID President 2015-2017 


ESID 2016 meeting

The 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID 2016) will be held September 21-24, 2016, in Barcelona, Spain. This meeting offers access to the latest research and analysis in the field of immunodeficiencies. Meeting participants will gain valuable insights into innovative perspectives in both basic and clinical research. ​ The scientific program will draw together leading international experts ​to discuss breakthroughs in diagnostic immunology, genetics and immunobiology of human diseases, advances in clinical practice, novel therapeutic approaches to tolerance induction and new insights into stem-cell and cellular therapies.